SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharma’s arm gets USFDA’s final nod for Clobetasol Propionate Foam

10 Sep 2019 Evaluate

Glenmark Pharmaceuticals’ subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Clobetasol Propionate Foam, 0.05% (Emulsion Formulation), a generic version of Olux®1?E Foam, 0.05%, of Mylan Pharmaceuticals Inc. 

According to IQVIA sales data for the 12 month period ending July 2019, the Olux?E Foam, 0.05% market achieved annual sales of approximately $11.1 million.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharma Share Price

2241.30 -6.60 (-0.29%)
20-Apr-2026 12:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1672.80
Dr. Reddys Lab 1238.00
Cipla 1238.25
Zydus Lifesciences 942.95
Lupin 2333.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×